Newsfeeds - Spark Newswire

1 minute read

Earnings

Recap: Regulus Therapeutics Q2 Earnings

August 10, 4:57 PM

Shares of Regulus Therapeutics (NASDAQ:RGLS) fell in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share increased 65.22% year over year to ($0.08), which were in line with the estimate of ($0.08).

RGLS

1 minute read

Regulus Therapeutics Q2 EPS $(0.08), Inline

By Benzinga Newsdesk

August 10, 4:57 PM

Regulus Therapeutics (NASDAQ:RGLS) reported quarterly losses of $(0.08) per share which met the analyst consensus estimate. This is a 65.22 percent increase over losses of $(0.23) per share from the same period last

RGLS

6 minute read

The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck’s Keytruda On Track For More Label Expansions, Eliem Debuts

By Shanthi Rexaline

August 10, 7:55 AM

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 9)

ACET

10 minute read

Earnings Scheduled For August 10, 2021

By Benzinga Insights

August 10, 4:05 AM

Companies Reporting Before The Bell • Nautilus Biotechnology (NASDAQ:NAUT) is expected to report earnings for its second quarter.

ABST

7 minute read

The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight

By Shanthi Rexaline

August 8, 10:03 AM

Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in, triggering stock-specific moves, while clinical readouts also moved stocks during the week.

ABCL

2 minute read

Movers

12 Health Care Stocks Moving In Friday’s After-Market Session

By Benzinga Insights

August 6, 4:31 PM

Gainers Nuwellis (NASDAQ:NUWE) shares increased by 5.63% to $4.5 during Friday's after-market session. The market value of their outstanding shares is at $29.3 million.

AQB